Skip to content
2000
Volume 23, Issue 1
  • ISSN: 1567-2018
  • E-ISSN: 1875-5704

Abstract

The global burden of Chronic Liver Diseases (CLDs) is escalating, with increasing prevalence and mortality. Various conditions ranging from fibrosis, cirrhosis, and hepatocellular carcinoma are associated with conditions such as toxin accumulation, viral infections, and metabolic derangements. In this already difficult context, the emergence of metabolic dysfunction-associated steatotic liver disease and steatohepatitis complicated the picture even further. While there has been much advancement in medical research, there is currently no standard cure; hence, the best treatment options are limited, providing a rising need for new therapeutic approaches. Nanoparticle drug delivery systems represent a promising avenue, providing targeted delivery and enhanced therapeutic effectiveness. Nanosystems can protect therapeutic agents from degradation, evade rapid clearance mechanisms, and target drugs directly to a specific hepatic cell type. However, the complex architecture of the liver presents challenges for these therapies, including the need to precisely target individual cells and retain the stability of nanoparticles within the hepatic microenvironment. This review presents recent advances in nanoparticle and targeted ligands-based technologies. These technologies help to navigate barriers associated with similar therapies. As these challenges are addressed, nanotechnological advancements could potentially lead to a major revolution in the treatment of CLDs, paving the way for improved management strategies and providing new hope for affected individuals worldwide.

© 2026 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cdd/10.2174/0115672018350438250311045745
2025-04-03
2026-03-01

  • From This Site

    /content/journals/cdd/10.2174/0115672018350438250311045745
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. CheemerlaS. BalakrishnanM. Global epidemiology of chronic liver disease.Clin. Liver Dis.202117536537010.1002/cld.1061 34136143
     [Google Scholar]
  2. MoonA.M. SingalA.G. TapperE.B. Contemporary epidemiology of chronic liver disease and cirrhosis.Clin. Gastroenterol. Hepatol.202018122650266610.1016/j.cgh.2019.07.060 31401364
     [Google Scholar]
  3. EskridgeW. CryerD.R. SchattenbergJ.M. GastaldelliA. MalhiH. AllenA.M. NoureddinM. SanyalA.J. Metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis: The patient and physician perspective.J. Clin. Med.20231219621610.3390/jcm12196216 37834859
     [Google Scholar]
  4. XueR. MengQ. The management of glucocorticoid therapy in liver failure.Front. Immunol.201910249010.3389/fimmu.2019.02490
     [Google Scholar]
  5. SingeapA.M. MineaH. PetreaO. RobeaM.A. BalmușI.M. DutaR. IlieO.D. CimpoesuC.D. StanciuC. TrifanA. Real-world utilization of corticosteroids in severe alcoholic hepatitis: Eligibility, response, and outcomes.Medicina202460231110.3390/medicina60020311 38399598
     [Google Scholar]
  6. AssimakopoulosS.F. ThomopoulosK.C. Labropoulou-KaratzaC. Pentoxifylline: A first line treatment option for severe alcoholic hepatitis and hepatorenal syndrome?World J. Gastroenterol.200915253194319510.3748/wjg.15.3194 19575503
     [Google Scholar]
  7. CaballeriaJ. Is there a role for pentoxifylline in the treatment of alcoholic hepatitis?Gastroenterol. Hepatol.201639856056510.1016/j.gastrohep.2015.10.004 26589540
     [Google Scholar]
  8. MinaiyanM. MazraatiP. Hepatoprotective effect of metadoxine on acetaminophen-induced liver toxicity in mice.Adv. Biomed. Res.2018716710.4103/abr.abr_142_17 29862216
     [Google Scholar]
  9. VuittonetC.L. HalseM. LeggioL. FricchioneS.B. BrickleyM. Haass-KofflerC.L. TavaresT. SwiftR.M. KennaG.A. Pharmacotherapy for alcoholic patients with alcoholic liver disease.Am. J. Health Syst. Pharm.201471151265127610.2146/ajhp140028 25027533
     [Google Scholar]
  10. YanJ. NieY. LuoM. ChenZ. HeB. Natural compounds: A potential treatment for alcoholic liver disease?Front. Pharmacol.20211269447510.3389/fphar.2021.694475 34290612
     [Google Scholar]
  11. GuL. ZhangF. WuJ. ZhugeY. Nanotechnology in drug delivery for liver fibrosis.Front. Mol. Biosci.2022880439610.3389/fmolb.2021.804396 35087870
     [Google Scholar]
  12. PradhanM. AlexanderA. Ajazuddin, Development and validation of a robust RP-HPLC method for analysis of calcipotriol in pharmaceutical dosage form.Res J Pharm Technol.201912257958310.5958/0974‑360X.2019.00103.3
     [Google Scholar]
  13. YadavK. SinghD. SinghM.R. PradhanM. Multifaceted targeting of cationic liposomes via co-delivery of anti-IL-17 siRNA and corticosteroid for topical treatment of psoriasis.Med. Hypotheses202014511032210.1016/j.mehy.2020.110322 33086162
     [Google Scholar]
  14. SinghD. PradhanM. NagM. SinghM.R. Vesicular system: Versatile carrier for transdermal delivery of bioactives.Artif. Cells Nanomed. Biotechnol.201543428229010.3109/21691401.2014.883401 24564350
     [Google Scholar]
  15. YadavK. PradhanM. SinghD. SinghM.R. Targeting autoimmune disorders through metal nanoformulation in overcoming the fences of conventional treatment approaches.Translational Autoimmunity. RezaeiN. Academic Press202236139310.1016/B978‑0‑12‑824390‑9.00017‑7
     [Google Scholar]
  16. EzhilarasanD. Advantages and challenges in nanomedicines for chronic liver diseases: A hepatologist’s perspectives.Eur. J. Pharmacol.202189317383210.1016/j.ejphar.2020.173832 33359144
     [Google Scholar]
  17. YadavR. PradhanM. YadavK. MahalvarA. YadavH. Present scenarios and future prospects of herbal nanomedicine for antifungal therapy.J. Drug Deliv. Sci. Technol.20227410343010.1016/j.jddst.2022.103430 35582019
     [Google Scholar]
  18. PradhanM. PariharA.K. SinghD. SinghM.R. Quality by design and formulation optimization using statistical tools for safe and efficient bioactive loading.Advances and Avenues in the Development of Novel Carriers for Bioactives and Biological Agents. ChauhanA. Academic Press202055559410.1016/B978‑0‑12‑819666‑3.00019‑5
     [Google Scholar]
  19. EzikeT.C. OkpalaU.S. OnojaU.L. NwikeC.P. EzeakoE.C. OkparaO.J. OkoroaforC.C. EzeS.C. KaluO.L. OdohE.C. NwadikeU.G. OgbodoJ.O. UmehB.U. OssaiE.C. NwangumaB.C. Advances in drug delivery systems, challenges and future directions.Heliyon202396e1748810.1016/j.heliyon.2023.e17488 37416680
     [Google Scholar]
  20. SinghS. SharmaN. ShuklaS. BehlT. GuptaS. AnwerM.K. Vargas-De-La-CruzC. BungauS.G. BriscC. Understanding the potential role of nanotechnology in liver fibrosis: A paradigm in therapeutics.Molecules2023286281110.3390/molecules28062811 36985782
     [Google Scholar]
  21. AcharyaP. ChouhanK. WeiskirchenS. WeiskirchenR. Cellular mechanisms of liver fibrosis.Front. Pharmacol.20211267164010.3389/fphar.2021.671640 34025430
     [Google Scholar]
  22. De MuynckK. VanderborghtB. Van VlierbergheH. DevisscherL. The gut-liver axis in chronic liver disease: A macrophage perspective.Cells20211011295910.3390/cells10112959 34831182
     [Google Scholar]
  23. KessokuT. KobayashiT. TanakaK. YamamotoA. TakahashiK. IwakiM. OzakiA. KasaiY. NogamiA. HondaY. OgawaY. KatoS. ImajoK. HigurashiT. HosonoK. YonedaM. UsudaH. WadaK. SaitoS. NakajimaA. The role of leaky gut in nonalcoholic fatty liver disease: A novel therapeutic target.Int. J. Mol. Sci.20212215816110.3390/ijms22158161 34360923
     [Google Scholar]
  24. RoohaniS. TackeF. Liver injury and the macrophage issue: Molecular and mechanistic facts and their clinical relevance.Int. J. Mol. Sci.20212214724910.3390/ijms22147249 34298870
     [Google Scholar]
  25. BourebabaN. MaryczK. Hepatic stellate cells role in the course of metabolic disorders development - A molecular overview.Pharmacol. Res.202117010573910.1016/j.phrs.2021.105739 34171492
     [Google Scholar]
  26. KammD.R. McCommisK.S. Hepatic stellate cells in physiology and pathology.J. Physiol.202260081825183710.1113/JP281061 35307840
     [Google Scholar]
  27. WilkinsonA.L. QurashiM. ShettyS. The role of sinusoidal endothelial cells in the axis of inflammation and cancer within the liver.Front. Physiol.20201199010.3389/fphys.2020.00990 32982772
     [Google Scholar]
  28. SinghM.R. YadavK. ChaurasiyaN.D. SinghD. Immune system and mechanism of immunomodulation.Plants and Phytomolecules for Immunomodulation: Recent Trends and Advances. SangwanN.S. FaragM.A. ModoloL.V. SingaporeSpringer Nature Singapore202213110.1007/978‑981‑16‑8117‑2_1
     [Google Scholar]
  29. LauA.H. ThomsonA.W. Dendritic cells and immune regulation in the liver.Gut200352230731410.1136/gut.52.2.307 12524419
     [Google Scholar]
  30. LurjeI. HammerichL. TackeF. Dendritic cell and T cell crosstalk in liver fibrogenesis and hepatocarcinogenesis: Implications for prevention and therapy of liver cancer.Int. J. Mol. Sci.20202119737810.3390/ijms21197378 33036244
     [Google Scholar]
  31. Nguyen-LefebvreA.T. HoruzskoA. Kupffer cell metabolism and function.J. Enzymol. Metab.20151
     [Google Scholar]
  32. SinghS.K. DwivediS.D. YadavK. ShahK. ChauhanN.S. PradhanM. SinghM.R. SinghD. Novel biotherapeutics targeting biomolecular and cellular approaches in diabetic wound healing.Biomedicines202311261310.3390/biomedicines11020613 36831151
     [Google Scholar]
  33. TiwariP. ShuklaR.P. YadavK. PanwarD. AgarwalN. KumarA. SinghN. BakshiA.K. MarwahaD. GautamS. RaiN. MishraP.R. Exploring nanocarriers as innovative materials for advanced drug delivery strategies in onco-immunotherapies.J. Mol. Graph. Model.202412810870210.1016/j.jmgm.2024.108702 38219505
     [Google Scholar]
  34. YadavH. MahalvarA. PradhanM. YadavK. Kumar SahuK. YadavR. Exploring the potential of phytochemicals and nanomaterial: A boon to antimicrobial treatment.Med. Drug Discov.20231710015110.1016/j.medidd.2023.100151
     [Google Scholar]
  35. SahuK. MinzS. PradhanM. KauravM. YadavK. Antiviral nanomaterials as potential targets for malaria prevention and treatment.Viral and Antiviral Nanomaterials.1st edCRC Press202240142410.1201/9781003136644‑21
     [Google Scholar]
  36. YadavK. SinghD. SinghM.R. MinzS. SahuK.K. KauravM. PradhanM. Dermal nanomedicine: Uncovering the ability of nucleic acid to alleviate autoimmune and other related skin disorders.J. Drug Deliv. Sci. Technol.20227310343710.1016/j.jddst.2022.103437
     [Google Scholar]
  37. SahuK.K. KauravM. BhattP. MinzS. PradhanM. KhanJ. SahuR.K. YadavK. 5 - Utility of nanomaterials in wound management.Nanotechnological Aspects for Next-Generation Wound Management. SolankiP.R. KumarA. Pratap SinghR. SinghJ. SinghK.R.B. Academic Press202410113010.1016/B978‑0‑323‑99165‑0.00006‑X
     [Google Scholar]
  38. MitchellM.J. BillingsleyM.M. HaleyR.M. WechslerM.E. PeppasN.A. LangerR. Engineering precision nanoparticles for drug delivery.Nat. Rev. Drug Discov.202120210112410.1038/s41573‑020‑0090‑8 33277608
     [Google Scholar]
  39. BodaghiA. FattahiN. RamazaniA. Biomarkers: Promising and valuable tools towards diagnosis, prognosis and treatment of Covid-19 and other diseases.Heliyon202392e1332310.1016/j.heliyon.2023.e13323 36744065
     [Google Scholar]
  40. HoraS. WuestefeldT. Liver injury and regeneration: Current understanding, new approaches, and future perspectives.Cells20231217212910.3390/cells12172129 37681858
     [Google Scholar]
  41. XuJ.H. YuY.Y. XuX.Y. Management of chronic liver diseases and cirrhosis: Current status and future directions.Chin. Med. J.2020133222647264910.1097/CM9.0000000000001084 32925282
     [Google Scholar]
  42. SandireddyR. SakthivelS. GuptaP. BehariJ. TripathiM. SinghB.K. Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases.Front. Cell Dev. Biol.202412143385710.3389/fcell.2024.1433857 39086662
     [Google Scholar]
  43. Chávez-LópezL.M. Carballo-LópezG.I. A comprehensive framework for managing metabolic dysfunction-associated steatotic liver disease: Analyzing novel risk factors and advances in nanotechnology-based treatments and diagnosis.RSC Med. Chem.202410.1039/D4MD00420E
     [Google Scholar]
  44. WangY. LaiR. ZongP. XuQ. ShangJ. ZhangX. ZhongW. TangJ. HanX. ChenC. MaoY. Bicyclol for the treatment of drug-induced liver injury: A propensity score matching analysis using a nationwide inpatient database.J. Int. Med. Res.20214940300060521100594510.1177/03000605211005945 33853430
     [Google Scholar]
  45. KhooT. LamD. OlynykJ.K. Impact of modern antiviral therapy of chronic hepatitis B and C on clinical outcomes of liver disease.World J. Gastroenterol.202127294831484510.3748/wjg.v27.i29.4831 34447229
     [Google Scholar]
  46. RasheedZ. Superoxide dismutase: Challenges, opportunities, and promises for clinical translation.Int. J. Health Sci.202418313 38721138
     [Google Scholar]
  47. PraharajD.L. AnandA.C. AcharyaS.K. Dosage of N-acetyl cysteine in acute liver failure not related to acetaminophen.J. Clin. Exp. Hepatol.202212272672810.1016/j.jceh.2022.01.002 35535093
     [Google Scholar]
  48. LiX. ZhouJ. ChenS. GuanM. WangY. ZhaoL. YingH. ZhouY. Role of bicyclol in preventing chemotherapeutic agent-induced liver injury in patients over 60 years of age with cancer.J. Int. Med. Res.201442490691410.1177/0300060514527058 24903556
     [Google Scholar]
  49. WenH. DengH. YangL. LiL. LinJ. ZhengP. BjelakovicM. JiG. Vitamin E for people with non-alcoholic fatty liver disease.Cochrane Libr.2024202410CD01503310.1002/14651858.CD015033.pub2 39412049
     [Google Scholar]
  50. MehedintM.G. ZeiselS.H. Choline’s role in maintaining liver function: New evidence for epigenetic mechanisms.Curr. Opin. Clin. Nutr. Metab. Care201316333934510.1097/MCO.0b013e3283600d46 23493015
     [Google Scholar]
  51. KimD.J. YoonS. JiS.C. YangJ. KimY.K. LeeS. YuK.S. JangI.J. ChungJ.Y. ChoJ.Y. Ursodeoxycholic acid improves liver function via phenylalanine/tyrosine pathway and microbiome remodelling in patients with liver dysfunction.Sci. Rep.2018811187410.1038/s41598‑018‑30349‑1 30089798
     [Google Scholar]
  52. LicataA. MinissaleM.G. StankevičiūtėS. Sanabria-CabreraJ. LucenaM.I. AndradeR.J. AlmasioP.L. N-acetylcysteine for preventing acetaminophen-induced liver injury: A comprehensive review.Front. Pharmacol.20221382856510.3389/fphar.2022.828565 36034775
     [Google Scholar]
  53. LangenM.L. MadsenK. Pre- and probiotics in liver health and function.Bioactive Foods in Promoting Health Probiotics and Prebiotics. PreedyH. BostonAcademic Press20109711610.1016/B978‑0‑12‑374938‑3.00007‑4
     [Google Scholar]
  54. PerazzaF. LeoniL. ColosimoS. MusioA. BocediG. D’AvinoM. AgnelliG. NicastriA. RossettiC. SacilottoF. MarchesiniG. PetroniM.L. RavaioliF. Metformin and the liver: Unlocking the full therapeutic potential.Metabolites202414418610.3390/metabo14040186 38668314
     [Google Scholar]
  55. SpoonerM.H. JumpD.B. Omega-3 fatty acids and nonalcoholic fatty liver disease in adults and children.Curr. Opin. Clin. Nutr. Metab. Care201922210311010.1097/MCO.0000000000000539 30601174
     [Google Scholar]
  56. WangC. MaC. GongL. DaiS. LiY. Preventive and therapeutic role of betaine in liver disease: A review on molecular mechanisms.Eur. J. Pharmacol.202191217460410.1016/j.ejphar.2021.174604 34743980
     [Google Scholar]
  57. PradhanM. SrivastavaS. SinghD. SarafS. SarafS. SinghM.R. Perspectives of lipid-based drug carrier systems for transdermal delivery.Crit. Rev. Ther. Drug Carrier Syst.201835433136710.1615/CritRevTherDrugCarrierSyst.2018020856 29972681
     [Google Scholar]
  58. MelgertB.N. OlingaP. Van Der LaanJ.M.S. WeertB. ChoJ. SchuppanD. GroothuisG.M.M. MeijerD.K.F. PoelstraK. Targeting dexamethasone to Kupffer cells: Effects on liver inflammation and fibrosis in rats.Hepatology200134471972810.1053/jhep.2001.27805 11584368
     [Google Scholar]
  59. YuX. ChenL. LiuJ. DaiB. XuG. ShenG. LuoQ. ZhangZ. Immune modulation of liver sinusoidal endothelial cells by melittin nanoparticles suppresses liver metastasis.Nat. Commun.201910157410.1038/s41467‑019‑08538‑x 30718511
     [Google Scholar]
  60. ShettyS. LalorP.F. AdamsD.H. Liver sinusoidal endothelial cells — gatekeepers of hepatic immunity.Nat. Rev. Gastroenterol. Hepatol.201815955556710.1038/s41575‑018‑0020‑y 29844586
     [Google Scholar]
  61. LeeA.R. NamK. LeeB.J. LeeS.W. BaekS.M. BangJ.S. ChoiS.K. ParkS.J. KimT.H. JeongK.S. LeeD.Y. ParkJ.K. Hepatic cellular distribution of silica nanoparticles by surface energy modification.Int. J. Mol. Sci.20192015381210.3390/ijms20153812 31387201
     [Google Scholar]
  62. MaH. DallasA. IlvesH. ShorensteinJ. MacLachlanI. KlumppK. JohnstonB.H. Formulated minimal-length synthetic small hairpin RNAs are potent inhibitors of hepatitis C virus in mice with humanized livers.Gastroenterology2014146636610.1053/j.gastro.2013.09.049
     [Google Scholar]
  63. D’SouzaA.A. DevarajanP.V. Asialoglycoprotein receptor mediated hepatocyte targeting — Strategies and applications.J. Control. Release201520312613910.1016/j.jconrel.2015.02.022 25701309
     [Google Scholar]
  64. PoissonJ. LemoinneS. BoulangerC. DurandF. MoreauR. VallaD. RautouP.E. Liver sinusoidal endothelial cells: Physiology and role in liver diseases.J. Hepatol.201766121222710.1016/j.jhep.2016.07.009 27423426
     [Google Scholar]
  65. BeljaarsL. MolemaG. WeertB. BonnemaH. OlingaP. GroothuisG.M. MeijerD.K. PoelstraK. Albumin modified with mannose 6-phosphate: A potential carrier for selective delivery of antifibrotic drugs to rat and human hepatic stellate cells.Hepatology19992951486149310.1002/hep.510290526 10216133
     [Google Scholar]
  66. RoehlenN. CrouchetE. BaumertT.F. Liver fibrosis: Mechanistic concepts and therapeutic perspectives.Cells20209487510.3390/cells9040875 32260126
     [Google Scholar]
  67. AzzamM. El SafyS. AbdelgelilS.A. WeiskirchenR. AsimakopoulouA. de LorenziF. LammersT. MansourS. TammamS. Targeting activated hepatic stellate cells using collagen-binding chitosan nanoparticles for siRNA delivery to fibrotic livers.Pharmaceutics202012659010.3390/pharmaceutics12060590 32630415
     [Google Scholar]
  68. KaźmierczakZ. Szostak-PaluchK. PrzybyłoM. LangnerM. WitkiewiczW. JędruchniewiczN. DąbrowskaK. Endocytosis in cellular uptake of drug delivery vectors: Molecular aspects in drug development.Bioorg. Med. Chem.2020281811555610.1016/j.bmc.2020.115556 32828419
     [Google Scholar]
  69. HashimM. MujahidH. HassanS. BukhariS. AnjumI. HanoC. AbbasiB.H. AnjumS. Implication of nanoparticles to combat chronic liver and kidney diseases: Progress and perspectives.Biomolecules20221210133710.3390/biom12101337 36291548
     [Google Scholar]
  70. MeisterP. DechêneA. BüchterM. KälschJ. GerkenG. CanbayA. JochumC. Spleen stiffness differentiates between acute and chronic liver damage and predicts hepatic decompensation.J. Clin. Gastroenterol.201953645746310.1097/MCG.0000000000001044 29738353
     [Google Scholar]
  71. PradhanM. SinghD. MurthyS.N. SinghM.R. Design, characterization and skin permeating potential of Fluocinolone acetonide loaded nanostructured lipid carriers for topical treatment of psoriasis.Steroids2015101566310.1016/j.steroids.2015.05.012 26049018
     [Google Scholar]
  72. SahuK.K. PradhanM. SinghD. SinghM.R. YadavK. Non-viral nucleic acid delivery approach: A boon for state-of-the-art gene delivery.J. Drug Deliv. Sci. Technol.20238010415210.1016/j.jddst.2023.104152
     [Google Scholar]
  73. SinghD. SrivastavaS. PradhanM. KanwarJ.R. SinghM.R. Inflammatory bowel disease: Pathogenesis, causative factors, issues, drug treatment strategies, and delivery approaches.Crit. Rev. Ther. Drug Carrier Syst.201532318121410.1615/CritRevTherDrugCarrierSyst.2015011095 26080808
     [Google Scholar]
  74. Rawat SinghM. SinghD. SahuK.K. PradhanM. YadavK. A method of preparation of Triamcinolone Acetonide encapsulated nanostructured lipid carriers for psoriasis treatment.Patent AU2021106678A4,2021
     [Google Scholar]
  75. YusufA. AlmotairyA.R.Z. HenidiH. AlshehriO.Y. AldughaimM.S. Nanoparticles as drug delivery systems: A review of the implication of nanoparticles’ physicochemical properties on responses in biological systems.Polymers2023157159610.3390/polym15071596 37050210
     [Google Scholar]
  76. SinghD. PradhanM. ShrivastavaS. MurthyS.N. SinghM.R. Chapter 11 - Skin autoimmune disorders: Lipid biopolymers and colloidal delivery systems for topical delivery. In: Nanobiomaterials in Galenic Formulations and Cosmetics Applications of Nanobiomaterials; William Andrew Publishing,20161025729610.1016/B978‑0‑323‑42868‑2.00011‑5
     [Google Scholar]
  77. YadavK. SinghD. SinghM.R. Protein biomarker for psoriasis: A systematic review on their role in the pathomechanism, diagnosis, potential targets and treatment of psoriasis.Int. J. Biol. Macromol.2018118Pt B1796181010.1016/j.ijbiomac.2018.07.021 30017989
     [Google Scholar]
  78. YadavK. SoniA. SinghD. SinghM.R. Polymers in topical delivery of anti-psoriatic medications and other topical agents in overcoming the barriers of conventional treatment strategies.Prog. Biomater.202110111710.1007/s40204‑021‑00154‑7 33738750
     [Google Scholar]
  79. Poilil SurendranS. George ThomasR. MoonM.J. JeongY.Y. Nanoparticles for the treatment of liver fibrosis.Int. J. Nanomedicine2017126997700610.2147/IJN.S145951 29033567
     [Google Scholar]
  80. MahmoudK. SwidanS. El-NabarawiM. TeaimaM. Lipid based nanoparticles as a novel treatment modality for hepatocellular carcinoma: A comprehensive review on targeting and recent advances.J. Nanobiotechnology202220110910.1186/s12951‑022‑01309‑9 35248080
     [Google Scholar]
  81. AgrawalM. SarafS. PradhanM. PatelR.J. SinghviG. AjazuddinA. AlexanderA. Design and optimization of curcumin loaded nano lipid carrier system using Box-Behnken design.Biomed. Pharmacother.202114111191910.1016/j.biopha.2021.111919 34328108
     [Google Scholar]
  82. PradhanM. AlexanderA. SinghM.R. SinghD. SarafS. SarafS. YadavK. Ajazuddin, Statistically optimized calcipotriol fused nanostructured lipid carriers for effectual topical treatment of psoriasis.J. Drug Deliv. Sci. Technol.20216110216810.1016/j.jddst.2020.102168
     [Google Scholar]
  83. AgrawalM. PradhanM. SinghviG. PatelR. AjazuddinA. AlexanderA. Thermoresponsive in situ gel of curcumin loaded solid lipid nanoparticle: Design, optimization and in vitro characterization.J. Drug Deliv. Sci. Technol.20227110337610.1016/j.jddst.2022.103376
     [Google Scholar]
  84. YadavK. SinghD. SinghM.R. PradhanM. Nano-constructs targeting the primary cellular energy source of cancer cells for modulating tumor progression.OpenNano2022810010710.1016/j.onano.2022.100107
     [Google Scholar]
  85. ElzoheiryA. AyadE. OmarN. ElbakryK. HyderA. Anti-liver fibrosis activity of curcumin/chitosan-coated green silver nanoparticles.Sci. Rep.20221211840310.1038/s41598‑022‑23276‑9 36319750
     [Google Scholar]
  86. AbdullahA.S. SayedI.E.T.E. El-TorgomanA.M.A. KalamA. WagehS. KamelM.A. Green synthesis of silymarin-chitosan nanoparticles as a new nano formulation with enhanced anti-fibrotic effects against liver fibrosis.Int. J. Mol. Sci.20222310542010.3390/ijms23105420 35628233
     [Google Scholar]
  87. YadavK. SahuK.K. SuchetaS.P.E. GnanakaniS.P.E. SureP. VijayalakshmiR. SundarV.D. SharmaV. AntilR. JhaM. MinzS. BagchiA. PradhanM. Biomedical applications of nanomaterials in the advancement of nucleic acid therapy: Mechanistic challenges, delivery strategies, and therapeutic applications.Int. J. Biol. Macromol.202324112458210.1016/j.ijbiomac.2023.124582 37116843
     [Google Scholar]
  88. NagoriK. NakhateK.T. YadavK. AjazuddinM. PradhanM. Unlocking the therapeutic potential of medicinal plants for Alzheimer’s disease: Preclinical to clinical trial insights.Future Pharmacol.20233487790710.3390/futurepharmacol3040053
     [Google Scholar]
  89. PradhanM. YadavK. SinghD. SinghM.R. Topical delivery of fluocinolone acetonide integrated NLCs and salicylic acid enriched gel: A potential and synergistic approach in the management of psoriasis.J. Drug Deliv. Sci. Technol.20216110228210.1016/j.jddst.2020.102282
     [Google Scholar]
  90. YadavK. SinghD. SinghM.R. Nanovesicles delivery approach for targeting steroid mediated mechanism of antipsoriatic therapeutics.J. Drug Deliv. Sci. Technol.20216510268810.1016/j.jddst.2021.102688
     [Google Scholar]
  91. YadavK. SinghD. SinghM.R. Development and characterization of corticosteroid loaded lipid carrier system for psoriasis.Res. J. Pharm. Technol.202114296697010.5958/0974‑360X.2021.00172.4
     [Google Scholar]
  92. YadavK. SinghD. SinghM.R. Novel archetype in psoriasis management bridging molecular dynamics in exploring novel therapies.Eur. J. Pharmacol.202190717425410.1016/j.ejphar.2021.174254 34118225
     [Google Scholar]
  93. PradhanM. AlexanderA. SinghM.R. SinghD. SarafS. SarafS. Ajazuddin, Understanding the prospective of nano-formulations towards the treatment of psoriasis.Biomed. Pharmacother.201810744746310.1016/j.biopha.2018.07.156 30103117
     [Google Scholar]
  94. MohantyA. UthamanS. ParkI.K. Utilization of polymer-lipid hybrid nanoparticles for targeted anti-cancer therapy.Molecules20202519437710.3390/molecules25194377 32977707
     [Google Scholar]
  95. SabuC. RejoC. KottaS. PramodK. Bioinspired and biomimetic systems for advanced drug and gene delivery.J. Control. Release201828714215510.1016/j.jconrel.2018.08.033 30165138
     [Google Scholar]
  96. TiwariP. YadavK. ShuklaR.P. GautamS. MarwahaD. SharmaM. MishraP.R. Surface modification strategies in translocating nano-vesicles across different barriers and the role of bio-vesicles in improving anticancer therapy.J. Control. Release202336329034810.1016/j.jconrel.2023.09.016 37714434
     [Google Scholar]
  97. TiwariP. ShuklaR.P. YadavK. SinghN. MarwahaD. GautamS. BakshiA.K. RaiN. KumarA. SharmaD. MishraP.R. Dacarbazine-primed carbon quantum dots coated with breast cancer cell-derived exosomes for improved breast cancer therapy.J. Control. Release2024365435910.1016/j.jconrel.2023.11.005 37935257
     [Google Scholar]
  98. PradhanM. SinghD. SinghM.R. Development characterization and skin permeating potential of lipid based novel delivery system for topical treatment of psoriasis.Chem. Phys. Lipids201518691610.1016/j.chemphyslip.2014.11.004 25447290
     [Google Scholar]
  99. YadavK. PradhanM. SinghD. SinghM.R. Macrophage-associated disorders: Pathophysiology, treatment challenges, and possible solutions.Macrophage Targeted Delivery Systems.Springer202210.1007/978‑3‑030‑84164‑5_4
     [Google Scholar]
  100. LeeM.S. KimN.W. LeeJ.E. KimM.G. YinY. KimS.Y. KoB.S. KimA. LeeJ.H. LimS.Y. LimD.W. KimS.H. ParkJ.W. LimY.T. JeongJ.H. Targeted cellular delivery of robust enzyme nanoparticles for the treatment of drug-induced hepatotoxicity and liver injury.Acta Biomater.20188123124110.1016/j.actbio.2018.09.023 30240953
     [Google Scholar]
  101. ShinnJ. ParkS. LeeS. ParkN. KimS. HwangS. MoonJ.J. KwonY. LeeY. Antioxidative hyaluronic acid-bilirubin nanomedicine targeting activated hepatic stellate cells for anti-hepatic-fibrosis therapy.ACS Nano20241864704471610.1021/acsnano.3c06107 38288705
     [Google Scholar]
  102. LiY. PuS. LiuQ. LiR. ZhangJ. WuT. ChenL. LiH. YangX. ZouM. XiaoJ. XieW. HeJ. An integrin-based nanoparticle that targets activated hepatic stellate cells and alleviates liver fibrosis.J. Control. Release2019303779010.1016/j.jconrel.2019.04.022 31004666
     [Google Scholar]
  103. DhokeD.M. BasaiyyeS.S. KhedekarP.B. Development and characterization of L-HSA conjugated PLGA nanoparticle for hepatocyte targeted delivery of antiviral drug.J. Drug Deliv. Sci. Technol.201847779410.1016/j.jddst.2018.06.006
     [Google Scholar]
  104. YuZ. GuoJ. LiuY. WangM. LiuZ. GaoY. HuangL. Nano delivery of simvastatin targets liver sinusoidal endothelial cells to remodel tumor microenvironment for hepatocellular carcinoma.J. Nanobiotechnology2022201910.1186/s12951‑021‑01205‑8 34983554
     [Google Scholar]
  105. HeX. ChangZ. ChenF. ZhangW. SunM. ShiT. LiuJ. ChenP. ZhangK. GuanS. ZhaoZ. LiM. DongW. ShaoD. YangC. Engineering a biomimetic system for hepatocyte-specific RNAi treatment of non-alcoholic fatty liver disease.Acta Biomater.202417428129610.1016/j.actbio.2023.10.038 37951519
     [Google Scholar]
  106. HouY.T. WuK.C.W. LeeC.Y. Development of glycyrrhizin-conjugated, chitosan-coated, lysine-embedded mesoporous silica nanoparticles for hepatocyte-targeted liver tissue regeneration.Materialia2020910056810.1016/j.mtla.2019.100568
     [Google Scholar]
  107. TanY. WangZ. GuoR. ZhouX. ZhangW. WuM. GuoC. GaoH. SunX. ZhangZ. GongT. Dual-targeting macrophages and hepatic stellate cells by modified albumin nanoparticles for liver cirrhosis treatment.ACS Appl. Mater. Interfaces2024169112391125010.1021/acsami.3c17670 38395769
     [Google Scholar]
  108. FuJ. ZhangP. SunZ. LuG. CaoQ. ChenY. WuW. ZhangJ. ZhuangC. ShengC. XuJ. LuY. WangP. A combined nanotherapeutic approach targeting farnesoid X receptor, ferroptosis, and fibrosis for nonalcoholic steatohepatitis treatment.Acta Pharm. Sin. B20241452228224610.1016/j.apsb.2024.02.017 38799646
     [Google Scholar]
  109. LiF. ZhaoY. ChengZ. WangY. YueY. ChengX. SunJ. Atabakhshi-KashiM. YaoJ. DouJ. YuJ. ZhangX. QiY. LiX. QiX. NieG. Restoration of sinusoid fenestrae followed by targeted nanoassembly delivery of an anti‐fibrotic agent improves treatment efficacy in liver fibrosis.Adv. Mater.20233517221220610.1002/adma.202212206 36862807
     [Google Scholar]
  110. PranatharthiharanS. PatelM.D. MalsheV.C. PujariV. GorakshakarA. MadkaikarM. GhoshK. DevarajanP.V. Asialoglycoprotein receptor targeted delivery of doxorubicin nanoparticles for hepatocellular carcinoma.Drug Deliv.2017241202910.1080/10717544.2016.1225856 28155331
     [Google Scholar]
  111. WangH. EllipilliS. LeeW.J. LiX. ViewegerM. HoY.S. GuoP. Multivalent rubber-like RNA nanoparticles for targeted co-delivery of paclitaxel and MiRNA to silence the drug efflux transporter and liver cancer drug resistance.J. Control. Release202133017318410.1016/j.jconrel.2020.12.007 33316298
     [Google Scholar]
  112. ZhangJ. ShenH. XuJ. LiuL. TanJ. LiM. XuN. LuoS. WangJ. YangF. TangJ. LiQ. WangY. YuL. YanZ. Liver-targeted siRNA lipid nanoparticles treat hepatic cirrhosis by dual antifibrotic and anti-inflammatory activities.ACS Nano20201456305632210.1021/acsnano.0c02633 32378877
     [Google Scholar]
  113. ColinoC.I. LanaoJ.M. Gutierrez-MillanC. Targeting of hepatic macrophages by therapeutic nanoparticles.Front. Immunol.20201121810.3389/fimmu.2020.00218 32194546
     [Google Scholar]
  114. SharmaR. PorterfieldJ.E. AnH-T. JimenezA.S. LeeS. KannanS. SharmaA. KannanR.M. Rationally designed galactose dendrimer for hepatocyte-specific targeting and intracellular drug delivery for the treatment of liver disorders.Biomacromolecules2021223574358910.1021/acs.biomac.1c00649
     [Google Scholar]
  115. UnagollaJ.M. DasS. FlanaganR. OehlerM. MenonJ.U. Targeting chronic liver diseases: Molecular markers, drug delivery strategies and future perspectives.Int. J. Pharm.202466012438110.1016/j.ijpharm.2024.124381 38917958
     [Google Scholar]
  116. WitzigmannD. UhlP. SieberS. KaufmanC. EinfaltT. SchöneweisK. GrossenP. BuckJ. NiY. SchenkS.H. HussnerJ. Meyer zu SchwabedissenH.E. QuébatteG. MierW. UrbanS. HuwylerJ. Optimization-by-design of hepatotropic lipid nanoparticles targeting the sodium-taurocholate cotransporting polypeptide.eLife20198e4227610.7554/eLife.42276 31333191
     [Google Scholar]
  117. WeiX. YangD. XingZ. CaiJ. WangL. ZhaoC. WeiX. JiangM. SunH. ZhouL. FanY. NieH. LiuH. Hepatocyte-targeted delivery using oleanolic acid-loaded liposomes for enhanced hepatocellular carcinoma therapy.Biomater. Sci.202311113952396410.1039/D3BM00261F 37102693
     [Google Scholar]
  118. SinghH. KimS.J. KangD.H. KimH.R. SharmaA. KimW.Y. KangC. KimJ.S. Glycyrrhetinic acid as a hepatocyte targeting unit for an anticancer drug delivery system with enhanced cell type selectivity.Chem. Commun.20185487123531235610.1039/C8CC05175E 30324188
     [Google Scholar]
  119. WenY. LambrechtJ. JuC. TackeF. Hepatic macrophages in liver homeostasis and diseases-diversity, plasticity and therapeutic opportunities.Cell. Mol. Immunol.2021181455610.1038/s41423‑020‑00558‑8 33041338
     [Google Scholar]
  120. MinayoshiY. MaedaH. YanagisawaH. HamasakiK. MizutaY. NishidaK. KinoshitaR. EnokiY. ImafukuT. ChuangV.T.G. KogaT. FujiwaraY. TakeyaM. SonodaK. WakayamaT. TaguchiK. IshimaY. IshidaT. IwakiriY. TanakaM. SasakiY. WatanabeH. OtagiriM. MaruyamaT. Development of Kupffer cell targeting type-I interferon for the treatment of hepatitis via inducing anti-inflammatory and immunomodulatory actions.Drug Deliv.20182511055106510.1080/10717544.2018.1464083 29688069
     [Google Scholar]
  121. MaedaH. IshimaY. SaruwatariJ. MizutaY. MinayoshiY. IchimizuS. YanagisawaH. NagasakiT. YasudaK. OshiroS. TauraM. McConnellM.J. OnikiK. SonodaK. WakayamaT. KinoshitaM. ShutoT. KaiH. TanakaM. SasakiY. IwakiriY. OtagiriM. WatanabeH. MaruyamaT. Nitric oxide facilitates the targeting Kupffer cells of a nano-antioxidant for the treatment of NASH.J. Control. Release202234145747410.1016/j.jconrel.2021.11.039 34856227
     [Google Scholar]
  122. LiuB. NguyenP.L. YuH. LiX. WangH. NguyenT.G.B. SahooP.K. SurM. ReddyJ. SillmanS. KachmanS.D. AltartouriB. LuG. NatarajanS.K. PattabiramanM. YuJ. Honey vesicle-like nanoparticles protect aged liver from non-alcoholic steatohepatitis.Acta Pharm. Sin. B20241483661367910.1016/j.apsb.2024.05.002 39220874
     [Google Scholar]
  123. HuJ. LiuJ. YangD. LuM. YinJ. Physiological roles of asialoglycoprotein receptors (ASGPRs) variants and recent advances in hepatic-targeted delivery of therapeutic molecules via ASGPRs.Protein Pept. Lett.201421101025103010.2174/0929866521666140626102429 24975671
     [Google Scholar]
  124. SatoY. MuraseK. KatoJ. KobuneM. SatoT. KawanoY. TakimotoR. TakadaK. MiyanishiK. MatsunagaT. TakayamaT. NiitsuY. Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-specific chaperone.Nat. Biotechnol.200826443144210.1038/nbt1396 18376398
     [Google Scholar]
  125. YadavK. GnanakaniS.P.E. SahuK.K. Veni ChikkulaC.K. VaddiP.S. SrilakshmiS. YadavR. SuchetaA. DubeyA. MinzS. PradhanM. Nano revolution of DNA nanostructures redefining cancer therapeutics—A comprehensive review.Int. J. Biol. Macromol.2024274Pt 113324410.1016/j.ijbiomac.2024.133244 38901506
     [Google Scholar]
  126. XuanJ. ChenY. ZhuL. GuoY. DengL. ZhengY. WangZ. WangZ. AoM. Ultrasound molecular imaging with cRGD-PLGA-PFOB nanoparticles for liver fibrosis staging in a rat model.Oncotarget201786510867610869110.18632/oncotarget.21358 29312560
     [Google Scholar]
  127. LiF. SunJ. WangJ. DuS. LuW. LiuM. XieC. ShiJ. Effect of hepatocyte growth factor encapsulated in targeted liposomes on liver cirrhosis.J. Control. Release20081311778210.1016/j.jconrel.2008.07.021 18692530
     [Google Scholar]
  128. MaslakE. GregoriusA. ChlopickiS. Liver sinusoidal endothelial cells (LSECs) function and NAFLD; NO-based therapy targeted to the liver.Pharmacol. Rep.201567468969410.1016/j.pharep.2015.04.010 26321269
     [Google Scholar]
  129. DilliardS.A. SiegwartD.J. Passive, active and endogenous organ-targeted lipid and polymer nanoparticles for delivery of genetic drugs.Nat. Rev. Mater.20238428230010.1038/s41578‑022‑00529‑7 36691401
     [Google Scholar]
  130. GilM. KhouriL. RaurellI. RafaelD. AndradeF. AbasoloI. SchwartzS.Jr Martínez-GómezM. SalcedoM.T. PericàsJ.M. HideD. WeiM. MetanisN. GenescàJ. MartellM. Optimization of statin-loaded delivery nanoparticles for treating chronic liver diseases by targeting liver sinusoidal endothelial cells.Pharmaceutics20231510246310.3390/pharmaceutics15102463 37896223
     [Google Scholar]
  131. ChakrabortyS. DlieZ.Y. ChakrabortyS. RoyS. MukherjeeB. BesraS.E. DewanjeeS. MukherjeeA. OjhaP.K. KumarV. SenR. Aptamer-functionalized drug nanocarrier improves hepatocellular carcinoma toward normal by targeting neoplastic hepatocytes.Mol. Ther. Nucleic Acids202020344910.1016/j.omtn.2020.01.034 32146417
     [Google Scholar]
  132. KaylanK.B. PaulS. NAFLD no more: A review of current guidelines in the diagnosis and evaluation of metabolic dysfunction-associated steatotic liver disease (MASLD).Curr. Diab. Rep.2025251510.1007/s11892‑024‑01558‑y 39535566
     [Google Scholar]
  133. KodaY. NagasakiY. Metabolic dysfunction-associated steatohepatitis treated by poly(ethylene glycol)-block-poly(cysteine) block copolymer-based self-assembling antioxidant nanoparticles.J. Control. Release202437036737810.1016/j.jconrel.2024.04.050 38692439
     [Google Scholar]
  134. ZhuM. ChengY. TangY. LiS. RaoP. ZhangG. XiaoL. LiuJ. Nanoparticles alleviate non-alcoholic steatohepatitis via ER stress sensor-mediated intestinal barrier damage and gut dysbiosis.Front. Microbiol.202414127183510.3389/fmicb.2023.1271835 38516345
     [Google Scholar]
  135. DoA. ZahrawiF. MehalW.Z. Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH).Nat. Rev. Drug Discov.202410.1038/s41573‑024‑01084‑2 39609545
     [Google Scholar]
  136. ChuR. WangY. KongJ. PanT. YangY. HeJ. Lipid nanoparticles as the drug carrier for targeted therapy of hepatic disorders.J. Mater. Chem. B Mater. Biol. Med.202412204759478410.1039/D3TB02766J 38682294
     [Google Scholar]
  137. TincopaM.A. AnsteeQ.M. LoombaR. New and emerging treatments for metabolic dysfunction-associated steatohepatitis.Cell Metab.202436591292610.1016/j.cmet.2024.03.011 38608696
     [Google Scholar]
  138. YuanY. LiJ. ChenM. ZhaoY. ZhangB. ChenX. ZhaoJ. LiangH. ChenQ. Nano-encapsulation of drugs to target hepatic stellate cells: Toward precision treatments of liver fibrosis.J. Control. Release202437631833610.1016/j.jconrel.2024.10.012 39413846
     [Google Scholar]
  139. AthanasopoulouF. ManolakakisM. VerniaS. KamalyN. Nanodrug delivery systems for metabolic chronic liver diseases: Advances and perspectives.Nanomedicine2023181678410.2217/nnm‑2022‑0261 36896958
     [Google Scholar]
  140. JoH. JungL. KimN. KimG.W. LeeD. Bile acid-based polydrug nanoparticles for the treatment of acute liver injury.Macromol. Res.202432541542610.1007/s13233‑023‑00241‑7
     [Google Scholar]
  141. LuJ. ZengY. ZhongH. GuoW. ZhangY. MaiW. QinY. SuX. ZhangB. WuW. ZhuY. HuangQ. YeY. Dual-stimuli-responsive gut microbiota-targeting nitidine chloride-cs/pt-nps improved metabolic status in NAFLD.Int. J. Nanomedicine2024192409242810.2147/IJN.S452194 38476281
     [Google Scholar]
  142. YadavK. SahuK.K. SuchetaS. MinzS. RazaW. PradhanM. Microtopographic influence on bacterial biofilm development in habitat-like environments.J. Drug Deliv. Sci. Technol.202410110631110.1016/j.jddst.2024.106311
     [Google Scholar]
  143. NiY. LiJ.M. LiuM.K. ZhangT.T. WangD.P. ZhouW.H. HuL.Z. LvW.L. Pathological process of liver sinusoidal endothelial cells in liver diseases.World J. Gastroenterol.201723437666767710.3748/wjg.v23.i43.7666 29209108
     [Google Scholar]
  144. BabociL. CapollaS. Di CintioF. ColomboF. MauroP. Dal BoM. ArgenzianoM. CavalliR. ToffoliG. MacorP. The dual role of the liver in nanomedicine as an actor in the elimination of nanostructures or a therapeutic target.J. Oncol.2020463819210.1155/2020/4638192
     [Google Scholar]
  145. WangY. YinZ. GaoL. MaB. ShiJ. ChenH. Lipid nanoparticles-based therapy in liver metastasis management: From tumor cell-directed strategy to liver microenvironment-directed strategy.Int. J. Nanomedicine2023182939295410.2147/IJN.S402821 37288351
     [Google Scholar]
  146. YinX. RongJ. ShaoM. ZhangS. YinL. HeZ. WangX. Aptamer-functionalized nanomaterials (AFNs) for therapeutic management of hepatocellular carcinoma.J. Nanobiotechnology202422124310.1186/s12951‑024‑02486‑5 38735927
     [Google Scholar]
  147. ElumalaiK. SrinivasanS. ShanmugamA. Review of the efficacy of nanoparticle-based drug delivery systems for cancer treatment.Biomed. Technol.20245109122
     [Google Scholar]
  148. SainzV. ConniotJ. MatosA.I. PeresC. ZupanǒiǒE. MouraL. SilvaL.C. FlorindoH.F. GasparR.S. Regulatory aspects on nanomedicines.Biochem. Biophys. Res. Commun.2015468350451010.1016/j.bbrc.2015.08.023 26260323
     [Google Scholar]
  149. MittalA. KumarN. ChauhanN.S. Curcumin encapsulated pegylated nanoliposomes: A potential anti-infective therapeutic agent.Indian J. Microbiol.201959333634310.1007/s12088‑019‑00811‑3 31388211
     [Google Scholar]
  150. CaoD. TianS. HuangH. ChenJ. PanS. Divalent folate modification on PEG: An effective strategy for improving the cellular uptake and targetability of PEGylated polyamidoamine-polyethylenimine copolymer.Mol. Pharm.201512124025210.1021/mp500572v 25514347
     [Google Scholar]
  151. VentolaC.L. Medical applications for 3D printing: Current and projected uses.P&T20143910704711 25336867
     [Google Scholar]
  152. MladenovskaT. ChoongP.F. WallaceG.G. O’ConnellC.D. The regulatory challenge of 3D bioprinting.Regen. Med.202318865967410.2217/rme‑2022‑0194 37403962
     [Google Scholar]
  153. YangZ. LiuX. CribbinE.M. KimA.M. LiJ.J. YongK.T. Liver-on-a-chip: Considerations, advances, and beyond.Biomicrofluidics202216606150210.1063/5.0106855 36389273
     [Google Scholar]
  154. DebnathS.K. DebnathM. GhoshA. SrivastavaR. OmriA. Targeting tumor hypoxia with nanoparticle-based therapies: Challenges, opportunities, and clinical implications.Pharmaceuticals20241710138910.3390/ph17101389 39459028
     [Google Scholar]
/content/journals/cdd/10.2174/0115672018350438250311045745
Loading
Precision Drug Delivery to the Liver: A Nanoparticle Approach
Curr. Drug Deliv. 23, 1 (2026); https://doi.org/10.2174/0115672018350438250311045745
/content/journals/cdd/10.2174/0115672018350438250311045745
/content/journals/cdd/10.2174/0115672018350438250311045745
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): Chronic liver diseases; cirrhosis; clinical translation; fibrosis; inflammation; metabolic dysfunction-associated steatotic liver disease; nanoparticle drug delivery; nanoparticles

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test